NSE: ABBOTINDIA | BSE: 500488

Expensive Performer

Download real time

30930.00 20.00 (0.06%)

10,009 NSE+BSE Volume

NSE 16 Sep, 2025 3:31 PM (IST)

65,724.1

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Abbott India Ltd.

12 Aug 2022

30930.00

0.06%

Result Update:Abbott India

Buy: Abbott India Ltd.

Target

Axis Direct

Abbott India's strategy of Beyond the Pill' comprising awareness, diagnosis, treatment and compliance for consumers is expected to deliver continued growth for the business. Therefore, we maintain a BUY rating on the stock with a Target Price of Rs 20,800/share.

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Abbott India Ltd.

11 Aug 2022

30930.00

0.06%

Margins contract; stock fairly priced

Hold: Abbott India Ltd.

Recommendation Target

ICICI Securities Limited

Abbott India’s (AIL) Q1FY23 performance was below our estimate on the profitability front.

Abbott India Ltd. is trading below its 30 day SMA of 32115.2

Abbott India Ltd.

18 May 2022

30930.00

0.06%

Result Update:Abbott India

Buy: Abbott India Ltd.

Axis Direct

We maintain a BUY rating on the stock with a Target Price of Rs 20,000/share.

Abbott India Ltd. is trading above its 200 day SMA of 30653.8

Abbott India Ltd.

18 May 2022

30930.00

0.06%

Abbott India

Buy: Abbott India Ltd.

ICICI Direct

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Abbott India Ltd.

11 Feb 2022

30930.00

0.06%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott's top 10 brands - (Mixtard, Thyronorm, Novomix, Udiliv, Duphaston) together posted revenue CAGR of ~7% MAT, December 2018-22 Abbott has 140+ brands in segments of women's health, gastroenterology,...

Abbott India Ltd. is trading below its 30 day SMA of 32115.2

Abbott India Ltd.

10 Feb 2022

30930.00

0.06%

Result Update:Abbott India

Buy: Abbott India Ltd.

Axis Direct

The company is expected to report Revenue/PAT CAGR of 11.1% and 11.3% 0ver FY21-FY24E backed by stable sales in the Duphaston brand, an increase in volume in the Thyronorm brand, and a pick-up in the IPM growth. Therefore, we recommend a BUY rating on the stock with a Target Price of Rs 20,000/share

Abbott India Ltd. is trading below its 30 day SMA of 32115.2

Abbott India Ltd.

10 Jan 2022

30930.00

0.06%

Pick of the Week:10 JAN 2022

Buy: Abbott India Ltd.

Target

Axis Direct

We recommend BUY with a TP of Rs 20,000/share.

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Abbott India Ltd.

15 Nov 2021

30930.00

0.06%

Result Update:Abbott India

Buy: Abbott India Ltd.

Recommendation Target

Axis Direct

We recommend a BUY rating on the stock with a Target Price of Rs 22,400/share.

Abbott India Ltd. is trading below its 30 day SMA of 32115.2

Abbott India Ltd.

22 Sep 2021

30930.00

0.06%

Axis Annual Analysis:Abbott India

Hold: Abbott India Ltd.

Target

Axis Direct

We expect Revenue/PAT CAGR of 11.1%/11.3% respectively over FY21-FY24E. While a TP of Rs 20,000 implies a marginal downside of 2.5%, we remain positive on the long-term outlook of the company and recommend a HOLD rating on the stock.

Abbott India Ltd. is trading above its 200 day SMA of 30653.8

Abbott India Ltd.

09 Aug 2021

30930.00

0.06%

Result Update:Abbott India

Hold: Abbott India Ltd.

Target

Axis Direct

We expect stable sales in the Duphaston brand and an increase in volume in the Thyronorm brand to result in revenue and PAT CAGR of 11.1% and 11.3% respectively 0ver FY21-FY24E. However, considering rich valuations (PE 40x for FY24E), we recommend HOLD with a target price of Rs 18,000/share.

Abbott India Ltd. has an average target of 35626.00 from 3 brokers.

Is Abbott India Ltd. worth buying?

309 Votes:

Buy 79.29%

Sell 10.68%

Hold 10.03%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf